Afabicin (Debio 1450) (Synonyms: Debio 1450; AFN-1720) |
| カタログ番号GC32295 |
アファビシン (Debio 1450) (Debio 1450) は、Debio1452 のプロドラッグであり、他のグラム陽性菌またはグラム陰性菌に対する有意な活性はなく、特にブドウ球菌を標的としています。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1518800-35-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Afabicin (Debio 1450) is the prodrug of Debio1452, specifically targeting staphylococci without significant activity against other Gram-positive or Gram-negative species. Debio1452 is an inhibitor FabI, an enzyme critical to fatty acid biosynthesis in staphylococci.
Afabicin (Debio1450) is the prodrug of Debio1452, specifically targeting staphylococci without significant activity against other Gram-positive or Gram-negative species. Debio1452 inhibits FabI, an enzyme critical to fatty acid biosynthesis in staphylococci. Debio1452 is highly active against staphylococci isolates, with MIC50 and MIC90 values of 0.015 μg/mL and 0.12 μg/mL, respectively. Debio1452 also inhibits S. aureus, with MICs of ≤0.12 μg/mL and MIC50 and MIC90 values of 0.004 μg/mL and 0.008 μg/mL, respectively[1].
[1]. Flamm RK, et al. Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. Antimicrob Agents Chemother. 2015 May;59(5):2583-7.
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *